Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Introduction: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms. Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R 2 = 0.99, interleukin (IL)10 R 2 = 0.95, fatty acid‐binding protein (FABP) R 2 = 0.94, I309 R 2 = 0.94, IL‐5 R 2 = 0.94, IL‐6 R 2 = 0.94, eotaxin3 R 2 = 0.91, IL‐18 R 2 = 0.87, soluble tumor necrosis factor receptor 1 R 2 = 0.85, and pancreatic polypeptide R 2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R 2 = 0.92, IL‐18 R 2 = 0.80, factor VII R 2 = 0.78, CRP R 2 = 0.74, and FABP R 2 = 0.70). Discussion: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationBelieve it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · cited 1×
“Despite tremendous scientific advancements, there remains a significant concern regarding the lack of reproducibility of research findings [1–4] with most believing that “at least 50%” of academic findings will not be replicable within industry laboratories [4].”
BackgroundPolicy: NIH plans to enhance reproducibility
Collins, F. S., & Tabak, L. A. (2014) · Nature · doi:10.1038/505612a · Cited by 1,247 · cited 1×
“In fact, the National Institutes of Health recently highlighted this problem and outlined a plan to address the issue [2].”
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“[26] identified a proteomic signature that was highly accurate in detecting and predicting AD; however, the findings did not cross validate across platforms [22].”
ResultAlzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · cited 3×
“Lovestone and colleagues have identified an association of clusterin with AD in genetic studies [27], using proteomics across multiple platforms [20,21], and within primary neurons [28].”
BackgroundSelf-citationClusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222
Self-citationDeveloping novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
Self-citationThe Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans
O'Bryant, S. E., for the Texas Alzheimer's Research & Care Consortium, Johnson, L., Edwards, M., Soares, H., Devous, M. D., Ross, S., Rohlfing, G., & Hall, J. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122071 · Cited by 47
Self-citation
Cited by
Shen, X.-N., Niu, L.-D., Wang, Y.-J., Cao, X.-P., Liu, Q., Tan, L., Zhang, C., & Yu, J.-T. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319148 · Cited by 388
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationO'Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., Lewczuk, P., Posner, H., Hall, J., Johnson, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.014 · Cited by 303
Self-citationHampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
Self-citationThe Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
“In this context, investigations in neurogenetics and neuroepigenetics have provided evolving findings of AD biomarkers over the last 20 years [48,49], neurochemistry [50]—having been done both on cerebrospinal fluid (CSF) [51,52] and blood [53,54]—additionally in structural, functional, and metabolic imaging [55,56],…”
Background
Metadata
- Authors
- O'Bryant, S. E., Lista, S., Rissman, R. A., Edwards, M., Zhang, F., Hall, J., Zetterberg, H., Lovestone, S., Gupta, V., Graff‐Radford, N., Martins, R., Jeromin, A., Waring, S., Oh, E., Kling, M., Baker, L. D., Hampel, H., & Area, I. B. B. B. P. I.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-12-29
- Volume
- 3
- Issue
- 1
- Pages
- 27-34
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2200373373
- Cited by
- 63
- References
- 8
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. https://app.cochat.ai/papers/10.1016/j.dadm.2015.12.003
- The paper
- O'Bryant, S. E., Lista, S., Rissman, R. A., Edwards, M., Zhang, F., Hall, J., Zetterberg, H., Lovestone, S., Gupta, V., Graff‐Radford, N., Martins, R., Jeromin, A., Waring, S., Oh, E., Kling, M., Baker, L. D., Hampel, H., & Area, I. B. B. B. P. I. (2016). Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2015.12.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.